Navin Pinto, MD is an attending physician at Seattle Children's Hospital and an Associate Professor of Pediatrics at the University of Washington School of Medicine. Dr. Pinto is a member of the Solid Tumor Program.
Dr. Navin Pintos interests and expertise focus on the use of genetic sequencing technologies to develop more personalized treatment strategies (pharmacogenomics) for children, adolescents and young adults with solid tumors. He completed his fellowship and laboratory training at the University Chicago. Dr. Pinto is board certified in General Pediatrics, Pediatric Hematology/Oncology and Clinical Pharmacology.
In addition to his work in pharmacogenomics, Dr. Pinto is interested in bringing novel treatments to patients with relapsed or refractory solid tumors. He is involved in several Phase I trials at Seattle Childrens Hospital and works with collaborative groups locally, nationally and internationally to bring new treatments to the clinic. He is an active member of the Childrens Oncology Group (COG), the New Approaches to Neuroblastoma Therapy (NANT) and the Genomic Assessment Informing Novel Therapeutics (GAIN) consortia.
Abstracts this author is presenting: